Agenus Inc. (NASDAQ:AGEN) rose 0.5% on Tuesday . The stock traded as high as $4.29 and last traded at $4.23, with a volume of 455,998 shares traded. The stock had previously closed at $4.21.

AGEN has been the topic of a number of research analyst reports. JMP Securities lowered their price target on Agenus from $17.00 to $15.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 9th. JPMorgan Chase & Co. lowered their price target on Agenus from $17.00 to $15.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 9th. Maxim Group raised Agenus from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, March 11th. HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Saturday, April 30th. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a report on Tuesday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Agenus has a consensus rating of “Buy” and an average price target of $10.47.

The stock’s market cap is $387.49 million. The stock has a 50-day moving average price of $4.04 and a 200-day moving average price of $3.78.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, April 28th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.14. On average, equities research analysts anticipate that Agenus Inc. will post ($1.41) EPS for the current year.

In related news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average price of $3.18 per share, with a total value of $318,000.00. Following the purchase, the chief executive officer now directly owns 1,346,026 shares in the company, valued at $4,280,362.68. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

A hedge fund recently raised its stake in Agenus stock. Wells Fargo & Company MN increased its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 177.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 332,554 shares of the company’s stock after buying an additional 212,599 shares during the period. Wells Fargo & Company MN owned about 0.39% of Agenus worth $1,510,000 at the end of the most recent quarter.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).